Full Papers
Pain catastrophising worsens RAPID3 in all rheumatologic conditions
J.-M. Berthelot1, G. Bart2, C. Darrieutort-Lafitte3, B. Le Goff4, P. Guillot5, J. Glémarec6, Y. Maugars7
- Service de Rhumatologie, Hôtel-Dieu, Nantes, France. jeanmarie.berthelot@chu-nantes.fr
- Service de Rhumatologie, Hôtel-Dieu, Nantes, France.
- Service de Rhumatologie, Hôtel-Dieu, Nantes, France.
- Service de Rhumatologie, Hôtel-Dieu, Nantes, France.
- Service de Rhumatologie, Hôtel-Dieu, Nantes, France.
- Service de Rhumatologie, Hôtel-Dieu, Nantes, France.
- Service de Rhumatologie, Hôtel-Dieu, Nantes, France.
CER11463
2019 Vol.37, N°4
PI 0600, PF 0607
Full Papers
PMID: 30620285 [PubMed]
Received: 18/06/2018
Accepted : 07/09/2018
In Press: 04/01/2019
Published: 27/06/2019
Abstract
OBJECTIVES:
To assess RAPID3 in various rheumatologic conditions, and the impact of pain catastrophising on RAPID3.
METHODS:
A set of questionnaires, including RAPID3 (0–30) and pain catastrophising score (0–52), was given to all outpatients seen in a one-month period: 518 patients fulfilled the questionnaires, including 127 RA (42% taking biologics), and 135 SpA (58% taking biologics).
RESULTS:
Mean pain catastrophising was 18.5±12.5, and 19% of patients could be classified as catastrophisers (>30). Higher RAPID3 scores were observed in the 33 osteoarthritis of lower limbs (16.44±5.20), 10 fibromyalgia (15.52±5.53), 47 back-pain (14.88±5.17), 17 osteoarthritis of upper limbs (13.61±7.42), and 38 tendinopathies (12.85±4.38). Lower RAPID3 were observed in the 135 SpA (12.79±6.03), 127 RA (12.18±6.30), 27 miscellaneous disorders (9.83±6.28), 7 entrapment neuropathies (9.81±4.51), 19 systemic connective tissue disorders (8.26±7.04) and 58 osteoporosis (7.85±6.95). Much higher RAPID3 scores were observed in the 19% with high pain catastrophising scores, whatever the conditions, and lower scores in the 15% with disablement benefits. RAPID3 was not associated with age or disease duration, but strongly correlated with daily fatigue, poor sleep, and length of daily pain.
CONCLUSIONS:
Thanks to progress made in RA and SpA treatment, higher RAPID3 scores were mostly observed in other rheumatic conditions, but co-morbidities and pain catastrophising might contribute to floor effects when assessing rheumatic disorders with RAPID3, hindering the recognition of low disease activity in some RA of SpA patients.